Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Subscribe To Our Newsletter & Stay Updated
